
Elasmogen presenting latest SDC data at Antibody Engineering & Therapeutics in Basel, June 10-12th 2025
Euan Murray (Senior Scientist) will attend Antibody Engineering & Therapeutics in Basel, June 10-12th 2025, and present a talk titled First-in-class Site-directed Targeted soloMER Drug Conjugate for Autoimmune Inflammation. He will describe the synthesis and...

Elasmogen presenting latest data at PEGS Summit in Boston, 12-16th May 2025
Stella Priyanka (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28, at PEGS Boston Summit, May 2025. Her poster, "Characterization of a Bi-Functional soloMER® Drug Conjugate (SDC) Targeting TNFα and JAK Enzymes...

Elasmogen to present new data at the Nextgen Biomed Conference, 12-14th March 2025
Dr Obinna C Ubah ((Principal Scientist and Future Leaders Fellow(UKRI)) and Dr Euan Murray (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28. Obinna's talk, "First-in-class Site-directed targeted soloMER Drug...

Elasmogen Presenting at World ADC Conference in London (3rd to 5th March 2025)
DR OBINNA C UBAH (Principal Scientist and Future Leaders Fellow (UKRI)) who leads our autoimmune inflammatory disease team is presenting new data on our lead first in class drug conjugate, ELN 28. His poster entitled, "Development and functional characterisation of...

Hands-on experience at Elasmogen for Harlaw Advanced Highers Students
It was fantastic to welcome and support Advanced Higher Biology pupils from Harlaw Academy again. The day began with some information about Elasmogen and drug discovery, followed by engaging discussions about two fundamental laboratory techniques and hands-on...

First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development
Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule (ALM-401), a First in Class Bispecific Antibody Drug Conjugate (ADC) for the treatment of refractory lung...

2024 Impact Report: The Scottish National Investment Bank helps Elasmogen to develop next-generation therapeutic drugs
https://www.youtube.com/watch?v=YpcwHA7GG0w Hear from Elasmogen's CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop next-generation therapeutic drugs, with the potential to improve the health of people in Scotland and globally.

Harlaw Academy students visited Elasmogen
On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR...

Elasmogen has been announced as a finalist for the Deal & Dealmakers Awards
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC Brewin Dolphin. Please see here the link to the story.